Addex Therapeutics (ADXN) Share-based Compensation (2019 - 2026)
Addex Therapeutics (ADXN) posted Share-based Compensation of $29.3 billion for Q1 2026, up 197.19% sequentially from -$30.1 billion in Q2 2025, and up 5.55% YoY from $27.7 billion in Q1 2025.
Addex Therapeutics (ADXN) Share-based Compensation (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $29.3 billion in Q1 2026.
- Quarterly Share-based Compensation rose 5.55% year-over-year to $29.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$511.6 billion (down 30.12% YoY) and the FY2025 annual result came in at $85418.0, down 85.06% from the prior year.
- Share-based Compensation climbed to $29.3 billion in Q1 2026 per ADXN's latest filing, from -$30.1 billion in the prior quarter.
- Over five years, Share-based Compensation peaked at $1025.2 billion in Q2 2023 and troughed at -$1584.2 billion in Q4 2023.
- A 5-year average of $2.4 billion and a median of $929835.9 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 149772522.7% in 2023, down 222878623.25% in 2023.
- Over 5 years, Share-based Compensation stood at $710802.1 in 2022, then plunged by 222878623.25% to -$1584.2 billion in 2023, then surged by 66.01% to -$538.5 billion in 2024, then surged by 94.41% to -$30.1 billion in 2025, then soared by 197.19% to $29.3 billion in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $29.3 billion, -$30.1 billion, and $27.7 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Addex Therapeutics | 515.38 Mn | 515.38 Mn | - | 29.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.25 Bn |
| Mar 31, 2026 | 29.25 Bn |
| Jun 30, 2025 | -30.10 Bn |
| Jun 30, 2025 | -30.10 Bn |
| Mar 31, 2025 | 27.71 Bn |
| Mar 31, 2025 | 27.71 Bn |
| Dec 31, 2024 | -538.46 Bn |
| Dec 31, 2024 | -538.46 Bn |
| Sep 30, 2024 | 544.44 Bn |
| Sep 30, 2024 | 544.44 Bn |
| Jun 30, 2024 | -426.87 Bn |
| Jun 30, 2024 | -426.87 Bn |
| Mar 31, 2024 | 442.27 Bn |
| Mar 31, 2024 | 442.27 Bn |
| Dec 31, 2023 | -1,584.23 Bn |
| Dec 31, 2023 | -1,584.23 Bn |
| Sep 30, 2023 | 547.36 Bn |
| Sep 30, 2023 | 547.36 Bn |
| Jun 30, 2023 | 1,025.20 Bn |
| Jun 30, 2023 | 1,025.20 Bn |